Director or Officer Departures, Elections, Appointments, and Compensation Arrangements

Business Context and Reporting Period

This Form 8-K is a current report filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp) on January 16, 2020. The registrant is incorporated in Nevada and trades on the Nasdaq Capital Market under the symbol EKSO. The report addresses Item 5.02 regarding compensatory arrangements for a named executive officer.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on executive compensation grants rather than financial performance results.

Material Changes

The material event reported is the Board of Directors' approval of new equity awards for Steven Sherman, the Company's Executive Chairman, effective January 16, 2020. The grants consist of:

  • 250,000 stock options to purchase common stock.
  • 200,000 restricted stock units (RSUs).

Both awards vest quarterly, beginning March 31, 2020. The RSUs settle upon the executive's separation of service.

Guidance, Outlook, and Risks

The filing contains no forward-looking guidance, market outlook, or discussion of specific risks or contingencies. It notes that full compensation details for the fiscal year ended December 31, 2019, will be disclosed in the upcoming Form 10-K or proxy statement.

Investor Verification Checklist

  • Verify the total number of shares authorized under the Amended and Restated 2014 Stock Incentive Plan to assess dilution impact.
  • Confirm the fair value of the granted options and RSUs in the subsequent Form 10-K.
  • Review the vesting schedule to understand the retention timeline for the Executive Chairman.
  • Check the upcoming proxy statement for the complete Summary Compensation Table for fiscal year 2019.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.